The Value of MultiSpectral 3 Tesla MRI in Active Surveillance of Prostate Cancer
NCT ID: NCT01896713
Last Updated: 2013-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
81 participants
INTERVENTIONAL
2010-04-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Active Surveillance Magnetic Resonance Imaging Study
NCT01354171
Prostate Screening Study Using MRI in BRCA Carriers
NCT01990521
Micro-Ultrasound/Magnetic Resonance Imaging 001
NCT03938376
Identifying Prostate Brachytherapy Seeds Using MRI
NCT01878058
Fiducial Localization and Individualized Radiotherapy -Prostate Cancer
NCT00789607
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic: Single Arm
Imaging (MS3TMRI)
MS3TMRI
Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MS3TMRI
Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinically eligible for radical prostatectomy and willing to undergo surgery
* Clinically eligible for and willing to undergo ultrasound biopsy within 8 weeks of MRI
Exclusion Criteria
* Contraindication to MRI
* Contraindication to receiving low molecular weight MRI contrast agent
* Prior hormone therapy except 5-alpha reductase inhibitors such as Avodart. FloMax etc
* Clinically suspected or known compromised renal function or calculated estimated Glomerular Filtration Rate (eGFR) \<30ml/min
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philips Healthcare
INDUSTRY
Sunnybrook Health Sciences Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Masoom Haider
Chief, Department of Medical Imaging
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Masoom Haider, MD
Role: PRINCIPAL_INVESTIGATOR
Sunnybrook Health Sciences Centre, University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
154-2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.